Abdulrahman Nasiri: A New Perspective on Avatrombopag in Aplastic Anemia
Abdulrahman Nasiri, Assistant Professor of Medicine and Hematology at Imam Mohammad Ibn Saud Islamic University, shared on LinkedIn:
“Kicking off 2026: A New Perspective on Avatrombopag in Aplastic Anemia
I am pleased to start the new year by sharing our latest review article, published in Therapeutic Advances in Hematology.
While Thrombopoietin Receptor Agonists (TPO-RAs) like Eltrombopag have revolutionized the treatment of Aplastic Anemia (AA), hepatotoxicity and dietary restrictions remain significant challenges for many patients.
Our team conducted a comprehensive review of clinical evidence from 2023 to 2025 to evaluate the efficacy and safety of Avatrombopag (AVA) as an alternative.
Key Findings for Clinical Practice:
- High Efficacy: Across the reviewed studies, we observed Overall Response Rates (ORR) ranging from 55% to 85%, with complete response rates reaching up to one-third of treated patients.
- Superior Liver Safety: Unlike earlier agents in this class, Avatrombopag demonstrated a favorable safety profile with no clinically relevant hepatotoxicity reported. It appears safe even for patients with underlying liver dysfunction.
- Rapid Response: Hematologic improvement typically occurred within 1–2 months, aligning well with clinical decision-making timelines.
- Patient Convenience: AVA requires no dietary restrictions and does not undergo significant hepatic metabolism, simplifying management for complex patients.
Title: Efficacy and safety of avatrombopag in aplastic anemia: a comprehensive review of clinical evidence
I extend my sincere gratitude to Dr. Mostafa Faisal Mohammed Saleh, Dr. Ahmed Kotb Abdrabou, Dr. Alfadil Haroon, Dr. Hadeel Samarkandi, Dr. Hazza Alzahrani, Dr. Mahmoud Aljurf, Dr. Ali Alahmari.
Read the full review here.”
Stay updated with Hemostasis Today.
-
May 28, 2026, 05:29Kidist K.: First Balloon Pulmonary Angioplasty Performed as New CTEPH Program Launches
-
May 28, 2026, 04:59Maria Sol Andres: Exploring Lipid Disorders in Modern Cancer Care
-
May 28, 2026, 04:42Francesca Granata: Representing the Porphyria Community at the 79th World Health Assembly
-
May 28, 2026, 04:29Samone Cook: When Collaboration Turns Into Organizational Coagulation
-
May 28, 2026, 03:42Lara Bloom: 15,000 Steps, Countless Conversations – One Unforgettable WHA79
-
May 27, 2026, 23:00Octavio Marques Pontes-Neto: Exchanging Latin American Experiences at the Global Stroke Alliance Meeting in Buenos Aires
-
May 27, 2026, 17:51Nita Radhakrishnan: Post Graduate Institute of Child Health Receives WFH Data Quality Certification for Excellence
-
May 27, 2026, 17:51Fiona Robinson: What exactly Are Rebalancing Agents for Bleeding Aisorders?
-
May 27, 2026, 17:14Khurram Nasir: Can Earlier LDL-C Lowering Change the Trajectory of Cardiovascular Disease?